Lytix Biopharma

Interim Report

Second quarter and first half-year 2025

Letter from the CEO

From Proof-of-Concept to Pivotal Milestones

Dear shareholders,

As we close the first half of 2025, Lytix Biopharma has made steady progress across our clinical, regulatory, and strategic priorities. While Q2 did not bring major public announcements, it was a pivotal quarter of preparation: aligning with FDA on the path to Phase III in basal cell carcinoma, completing treatment in our late-stage melanoma study, advancing patient enrollment in the NeoLIPA trial and strengthening both the board and the management with commercial biotech competence. Together, these steps position us for a decisive period in the second half of the year.

Step by step, moving closer to patients
Our clinical development is progressing well, with several milestones in the coming period. We are transitioning from clinical validation to preparing for broader clinical impact and ultimately market entry. With our lead candidate, LTX-315, we're now moving from late-stage, treatment-resistant cancer to earlier-stage, potentially curative settings. We are also pleased to announce that our lead drug candidate, previously known as LTX-315, now carries its official international non-proprietary name (INN): **Ruxotemitide**, underscoring the maturity of our program and its progress towards becoming a future marketed medicine.

Verrica partnership: advancing toward Phase III in basal cell carcinoma
Our partner Verrica Pharmaceuticals has continued to advance the development of Ruxotemitide (VP-315) for basal cell carcinoma (BCC). Following the impressive phase II results presented in 2024, a successful end-of-Phase II meeting with the FDA in the spring of 2025 provided valuable guidance on the path to a pivotal Phase III study. Ruxotemitide's clinical potential has also been presented in multiple scientific forums, including three posters presented at the Winter Clinical Dermatology Conference in Florida earlier this year.

Verrica has confirmed that preparations for Phase III are in process, including exploring non-dilutive opportunities for financing further development of Ruxotemitide. Worth noting, Verrica has announced that additional genomic and immune response data, along with a comprehensive development update on Ruxotemitide, will be shared later this year at a scientific conference.

The transition into Phase III represents a key inflection point, and the initiation of this program could unlock significant value for Ruxotemitide in basal cell carcinoma, the most common form of skin cancer.

Moving from end-stage to earlier-stage cancer patients
A significant achievement in the first half of the year was the completion of patient treatment in our ATLAS-IT-05 trial, a Phase II study in late-stage metastatic melanoma. This marks an important chapter in our development program. The study

confirmed disease control in approximately 40% of the treated patients who had failed to respond to other treatment options. Encouragingly, tumor regression was observed not only in injected tumors, but also in distant non-treated metastases. The effects obtained in non-treated tumors are intriguing since these patients often have a weakened immune system.

To increase the likelihood of strong immune responses we have decided to progress Ruxotemitide development in earlier disease stages where the immune system is more robust and the therapeutic potential greater.

This strategy is now fully embodied in the ongoing **NeoLIPA** trial, evaluating Ruxotemitide as a neoadjuvant treatment for patients with early-stage melanoma. This study is not only aiming to reduce the size of the treated tumor before surgery, but to potentially reduce the risk of relapse by priming the patient's immune system. About a third of the patients have been treated so far and we are very much looking forward to the presentation of the first interim results from this study at the Nordic Melanoma Meeting in Tromsø, November 11, 2025.

Strategic focus on developing Ruxotemitide for neoadjuvant cancer therapy

Based on what we have learned from our studies and discussions with clinical advisors, we consider that LTX-315 used in a neoadjuvant setting before surgical removal of the resectable tumors represents an optimal development path for LTX-315. LTX-315 has demonstrated the ability to trigger robust effects locally through intratumoral administration and systemic immune responses that can eradicate cancer cells elsewhere in the body and potentially protect against relapses of the cancer disease following surgery. Hence LTX-315 should be particularly suited in a neoadjuvant setting.

The ongoing NeoLIPA trial will be an important source of insight where positive data could support the case for Ruxotemitide in a neoadjuvant setting. Based on interim results and depending on the final result, Lytix is actively looking at options to design the shortest path to market.

To support this next phase, we are also strengthening our team to enhance our capabilities in business development and regulatory strategy, which also reflects an expansion from clinical exploration to commercialization preparation.

While our current focus is on maximizing the opportunities with Ruxotemitide, which is moving rapidly toward key value-driving milestones, we are actively designing plans to advance the LTX-401 to reach the clinics as soon as possible.

Staying grounded in the patient perspective

We should not forget all the patients who participate in our trials, and the transition from end-stage treatment to neoadjuvant care reflects our commitment to making a meaningful difference earlier in the patient's disease journey, which may reduce the number of hospitals visits, provide less physical and emotional burden and potentially improve overall outcome.

We remain deeply grateful to the patients, clinicians, partners and shareholders who make our progress possible.

Looking ahead

With new data emerging from Verrica's Phase II study, greater clarity around their Phase III plans, alongside interim results from NeoLIPA expected later this year, Lytix Biopharma is entering a milestone-rich period, one that could accelerate our path toward commercialization and amplifies our potential for broader clinical impact.

Thank you for your continued trust and support.

Sincerely,

Øystein Rekdal
CEO and co-founder
Lytix Biopharma

Highlights and key figures

Highlights for the first half of 2025 and post-periodic events

Partnership:

- Verrica presented three scientific posters at the 2025 Winter Clinical Dermatology Conference in Florida, underlining both the potential of Ruxotemitide (LTX-315) in basal cell carcinoma (BCC) and the strength of Lytix's oncolytic technology platform
- In Q2, Verrica reported an encouraging End-of-Phase II meeting with FDA for Ruxotemitide in BCC, resulting in alignment on advancing the program into a pivotal Phase III trial
- Verrica plans to present a comprehensive update on the clinical development plan with Ruxotemitide in BCC program, including genomic and immune response data, at a scientific conference later in 2025

Clinical progress:

- **ATLAS-IT-05:** Patient recruitment and treatment are completed. The preparation of the clinical study report is underway
- **NeoLIPA:** The neoadjuvant setting represents a compelling path for immunotherapy, aiming to improve long-term outcomes by activating anti-tumor immunity before surgery. Interim results are expected to be presented at the Nordic Melanoma meeting November 11, 2025. One third of the patients have been treated to date
- **LTX-401:** Actively designing plans to advance the asset to reach the clinics as soon as possible

Organization:

- Strengthening executive team and board, to support commercial readiness and partnership activities

Business and Financial:

- Cash and short-term financial investments totaled NOK 100.3 million at the end of the period.
- Accruals for the ATLAS-IT-05 study were reduced by NOK 10.2 million following updated cost data showing significantly lower Keytruda prices at European trial sites. The adjustment reversed previously recorded expenses, with no cash impact.

KEY FIGURES

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**FY 2024**
Total operating income	**-**	-	**-**	10,526	**11,134**
Total operating expense	**(5,157)**	(21,540)	**(18,608)**	(50,751)	**(107,029)**
Loss from operations	**(5,157)**	(21,540)	**(18,608)**	(40,225)	**(95,896)**
Loss for the period	**(5,051)**	(21,435)	**(17,984)**	(39,617)	**(94,265)**
Property, plant and equipment			**18**	76	**42**
Right of use asset			**2,565**	2,998	**2,589**
Trade and other receivables			**7,281**	14,410	**13,113**
Short-term financial investments			**60,072**	-	**-**
Cash position at the end of the period			**40,191**	60,181	**130,791**
Total assets			**110,127**	**77,665**	**146,535**
Total equity			**90,024**	59,221	**107,894**
Total liabilities			**20,103**	18,444	**38,641**
Total equity and liabilities			**110,127**	**77,665**	**146,535**

Review of the first half-year 2025

Operational Review

Partnerships

Ruxotemitide development in partnership with Verrica

Following the compelling Phase II results announced in August 2024, which demonstrated high rates of responses and significant tumor reduction in patients with basal cell carcinoma (BCC), Verrica has continued to advance the Ruxotemitide (LTX-315) program towards Phase III. The positive data reinforces Ruxotemitide's potential as a non-surgical treatment for skin cancers and provides a robust foundation towards late-stage development and commercialization.

In January 2025, Verrica showcased three scientific posters at the Winter Clinical Dermatology Conference in Florida, presenting both the promising clinical outcomes from the Phase II trial and the broader potential of Lytix's oncolytic peptide platform. The presentations underscored Ruxotemitide's potential to either replace or complement surgery, offering a differentiated and potentially transformative option for patients.

Verrica also held a productive End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA), resulting in broad alignment on the advancement into a pivotal Phase III program for BCC. This regulatory milestone provides a clear development pathway toward registration and underscores the program's potential to redefine the standard of care for BCC, the most common form of cancer worldwide.

Looking ahead, Verrica will present a comprehensive update on the BCC program at a scientific conference later this year, including new genomic and immune response data. These results will offer further insight into Ruxotemitide's dual mechanism of action and its potential to deliver durable, long-term benefits for patients. With both parties aligned on bringing the product to market swiftly, Lytix is positioned to capture upcoming milestone opportunities.

Research and development

ATLAS-IT-05 trial (Ruxotemitide in combination with pembrolizumab in advanced melanoma)

The ATLAS-IT-05 trial has now been successfully completed, marking a significant milestone for Lytix Biopharma. The study investigated the intratumoral immune activator Ruxotemitide in combination with pembrolizumab (Keytruda®) in patients with advanced, treatment-resistant metastatic melanoma who had previously failed PD-1/PD-L1 immune checkpoint inhibitor therapy. These patients represented a highly challenging population, typically with rapid disease progression, high tumor burden, and severely compromised immune systems.

Despite this, the trial demonstrated a disease control rate of approximately 40%, with some patients experiencing prolonged disease stabilization lasting up to 22 months. Durable partial responses were observed in two patients, and signs of systemic immune activity were seen, including responses in distant, non-injected lesions. Notably, Ruxotemitide continued to show a favorable safety profile, with adverse events primarily limited to local injection site reactions of mild to moderate intensity.

ClinicalTrials.gov Identifier: NCT04796194

NeoLIPA study (ATLAS-IT-06 – Ruxotemitide in a neoadjuvant setting in early-stage melanoma)

Since Ruxotemitide is more likely to succeed in earlier disease settings where patients have stronger immune systems and lower tumor burden, Lytix is strategically prioritizing the development of LTX-315 in neoadjuvant setting

(treatment before surgery), an area of growing scientific and regulatory interest for immunotherapies. The NeoLIPA study is designed to generate critical data that will inform whether this setting can represent a viable path forward.

It is well accepted that immunotherapy can be more effective when used in the neoadjuvant setting, since this patient population often has a more robust immune system that will respond better to immunotherapy than late-stage cancer patients with a more weakened immune system. By targeting tumors locally through intratumoral injections and simultaneously activating the patient's immune system, Ruxotemitide has the potential to both shrink tumors ahead of surgery and prime the immune system to prevent recurrence. This dual mechanism offers the potential to improve long-term outcomes beyond what is achievable with checkpoint inhibitors alone.

The investigator-initiated NeoLIPA study is progressing well, with patient enrollment and treatment ongoing at Oslo University Hospital, Radiumhospitalet. As of the reporting date, 9 patients have been treated. Interim results from the study are expected to be presented by Principal Investigator Dr. Henrik Jespersen at the Nordic Melanoma Meeting in Tromsø, Norway, November 11th, 2025. The Nordic Melanoma Meeting brings together clinicians and researchers from the Nordic countries as well as leading international melanoma scientists.

NeoLIPA is a phase II, open-label study assessing the use of Ruxotemitide in combination with pembrolizumab (Keytruda®) as a neoadjuvant treatment, i.e. before surgery, in patients with fully resectable stage III-IV melanoma. The goal is to evaluate whether this combination can reduce tumor burden ahead of surgery and stimulate a systemic immune response that may reduce the risk of relapse post-operatively.

Positive results from the NeoLIPA trial would be a clear indication of positioning Ruxotemitide in a neoadjuvant setting expanding the potential commercial opportunity of Ruxotemitide in other indications, such as triple-negative breast cancer (TNBC) or Merkel cell carcinoma (MCC).

EU-CT No: 2023-508649-42-00

LTX-401

LTX-401 remains an important long-term asset in our pipeline, with strong preclinical data and significant market potential. The improved formulation has demonstrated superior anti-cancer efficacy in difficult-to-treat tumor models and offer enhanced intellectual property protection.

In December 2024, Lytix received constructive scientific advice from European regulatory authorities on key aspects of a potential clinical program, including formulation, manufacturing, dosing, and safety assessments. This feedback confirms alignment with regulatory expectations and ensures that the program is well-prepared for a future transition into clinical development.

The Company is actively designing plans to advance the asset to reach the clinics as soon as possible.

Business

Strengthening leadership and governance to drive global growth and late-stage execution

During the first half of 2025, Lytix Biopharma has taken important steps to strengthen its leadership, governance, and commercial capabilities in line with its strategy to advance clinical programs and prepare for future market opportunities. Following the appointments of Dr. Ahmed Bouzidi as Senior Vice President Business Development and Brent Meadows as Chief Business Officer earlier this year, the company has further reinforced its organizational platform with the election of a new Board of Directors at the Annual General Meeting.

The newly appointed board, chaired by Eric Falcand, brings a broad and complementary mix of expertise across oncology drug development, business development, global commercialization, regulatory strategy, and corporate finance. This combination of senior management and board-level capabilities provides a stronger foundation for late-stage deal execution, international partnering, and long-term value creation.

With these additions, Lytix is better positioned to accelerate the development of its immuno-oncology pipeline, expand its network of strategic collaborations, and bring innovative treatment options to patients with cancer worldwide. The first half of the year has therefore been marked not only by clinical progress in the pipeline, but also by significant organizational advancements that will support the company's transition toward the next phases of growth.

Financial review

Accounting policies

These interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 "Interim Financial Reporting" as adopted by the European Union (the "EU") and additional requirements in the Norwegian Securities Trading Act. This interim financial report does not include all information and disclosures required by other standards within IFRS® Accounting Standards as adopted by the EU ("IFRS") for a complete set of annual financial statements. Hence, this report should be read in conjunction with the annual report prepared in accordance with IFRS for the year ended 31 December 2024.

Profit and loss

Personnel expenses for the first half of 2025 came in at NOK 7.7 million (NOK 10.4 million for the first half of 2024). The decrease reflects a combination of factors, including lower one-time costs compared to the prior year, timing effects in bonus and option expenses, and overall cost discipline across the organization.

Depreciation and amortization expenses were stable at NOK 0.5 million for the first half of 2025 compared to NOK 0.5 for the same period 2024. The majority is depreciation of leased assets.

Direct R&D expenses amounted to NOK 3.1 million for the first half of 2025 (NOK 33.4 million for the same period in 2024). During the second quarter of 2025, Lytix identified that previously recorded accruals for the ATLAS-IT-05 melanoma study were overstated by NOK 10.2 million. The original estimate for the cost of Keytruda, which is administered at European trial sites, had been based on U.S. pricing. As the European cost of Keytruda is significantly lower, the accruals were adjusted accordingly in Q2 2025. This correction resulted in a reversal of a portion of the previously recognized expenses, with no impact on the company's cash position. In addition to this reversal the decreased direct R&D expenses for the first half is a result of lower clinical activity as ATLAS-IT-05 is in its closure phase.

Other operating expenses amounted to NOK 7.4 million for the first half of 2025 compared to NOK 6.5 million for the same period last year. The increase mainly reflects costs related to the recruitment of new board members and the expansion of business development capabilities.

Loss from operations for the first six months of 2025 amounted to NOK 18.6 million compared to NOK 40.2 million for the same period in 2024.

Net financial items contributed positively to the net result with NOK 0.6 million in the first half of 2025 (NOK 0.6 million). The net financial income primarily reflects interest earned on bank deposits and short-term investments.

Cash flow

Cash flow from operating activities amounted to negative NOK 30.4 million in the first half of 2025, compared with negative NOK 37.2 million for the first half of 2024.

Cash flow from investing activities in the first half of 2025 amounted to negative NOK 59.8 million (NOK 23.5 million) and is mainly related to a placement of excess liquidity in a liquidity fund.

Cash flow from financing activities for the first half of 2025 amounted to negative NOK 0.4 million (NOK 46.5 million for the same period last year). The negative cash flow from financing activities is mainly due to leasing expenses.

Statement of financial position / balance sheet

Cash and cash equivalents at the end of the reporting period amounted to NOK 40.2 million, compared with NOK 130.8 million as of 31 December 2024 and NOK 60.2 million as of 30 June 2024. At the end of the reporting period cash and cash equivalents plus short-term financial investments were NOK 100.3 million.

As of June 30, 2025, Lytix had total assets of NOK 110.1million, compared to NOK 146.5 million by the end of 2024, and NOK 77.7 million by June 30, 2024.

Total equity amounted to NOK 90.0 million by June 30, 2025, compared to NOK 107.9 million by the end of 2024 and NOK 59.2 million by June 30, 2024. The equity ratio amounted to 81.7 percent as of June 30, 2025, compared to 73.6 percent by the end of 2024 and 76.3 percent by June 30, 2024.

Total liabilities amounted to NOK 20.1 million by June 30, 2025, compared to NOK 38.6 million by end of 2024 and NOK 18.4 million by June 30, 2024.

Platform technology

Lytix' technology platform is based on solid preclinical and clinical research and originates from UiT, The Arctic University of Norway, Tromsø. The company has successfully generated several highly active oncolytic molecules from naturally occurring host defense peptides. These have the potential to address the main challenge to deal efficiently with cancer; the heterogeneity of the tumor, enabling the cancerous cells to escape various targeting therapies.

Generating a systemic and lasting anti-tumor immunity

Oncolytic molecules work by a dual mode of action, killing of cancer cells and activating the immune system. When these molecules are injected straight into the tumor environment, they both kill cancer cells and potentiate the patient’s immune system. Lytix’ approach represents an alternative and unique treatment approach to active the patient’s own immune system to fight cancer. So far, data has demonstrated that Lytix’ molecules can generate a systemic and lasting anti-tumor immunity.

Lytix' oncolytic molecules kill cancer cells in a unique way resulting in an efficient release of tumor neoantigens (mutated proteins) and immune activating molecules. This process results in the activation of the patient's own killer T cells which will enter circulation and search for and kill cancer cells.

The oncolytic molecules are also ideal for combination with other types of immune therapies where the lack of immune cells in the patients' tumors is one of the major hurdles for these therapies to be effective.



Oncology is the largest pharmaceutical market by revenue. Oncology therapeutics represented USD 184 billion in sales in 2021 (˜20% of global pharmaceutical sales) [1]. To capture a larger market share, parallel development across multiple indications, increases the value of an individual asset and makes deal-making more likely. Unmet need remains high, and the market is expected to reach $269 billion by 2025 [2]. The key driver behind this future growth is expected to be immuno-oncology combination therapies. Lytix' oncolytic molecules are synergistic and complementary to other immuno-oncology therapies with the potential to create new treatment paradigms.

By addressing the main challenge across a wide section of cancer indications as well as being able to combine with many other immuno-oncology therapies, Lytix' oncolytic molecules have the potential to claim a unique position within immuno-oncology, creating significant patient impact as well as value for Lytix.

Product candidates and portfolio

Lytix Biopharma's unique oncolytic technology platform offers a whole range of product opportunities and has the capacity to improve the lives of patients across many types of cancer.

The developmental program is progressing the oncolytic molecules both as monotherapy, as a combination partner with checkpoint inhibitors and as an adjunct to cell therapy.

Lytix's lead product, Ruxotemitide, is recently tested in three Phase II trials (two completed and one ongoing) as a monotherapy and in combination with pembrolizumab.

Lytix' ATLAS-IT-05 clinical trial with Ruxotemitide was initiated at the MD Anderson Cancer Centre in the US and expanded to six sites in Europe. The study recruited patients with metastatic melanoma, a patient population with a significant unmet medical need.

LTX-401 is a second-generation candidate drug; it is a small molecule and seems to be ideal for deep-seated tumors such as liver cancer. A new and improved formulation of LTX-401 offers potentially strong intellectual property protection and improved anticancer efficacy in preclinical models.

[1] Source: IQVIA Research, 2023
[2] Source: IQVIA Research, 2023



Partnerships

Verrica Pharmaceuticals Inc.

Verrica is a Nasdaq-listed dermatology therapeutics company developing medications for skin diseases requiring medical interventions, and it is headquartered in West Chester, Pennsylvania. In August 2020, Lytix announced that it entered into a license agreement providing Verrica with a world-wide license to develop and commercialize Ruxotemitide for all malignant and pre-malignant dermatological indications (skin cancer). Lytix maintains all rights to the use of Ruxotemitide in patients with metastatic melanoma and metastatic Merkel cell carcinoma. Verrica will assume responsibility for manufacturing the Ruxotemitide drug product, while Lytix retains responsibility for manufacturing of the active pharmaceutical ingredient (API).

Under the exclusive worldwide license agreement with Verrica, Lytix has received an upfront payment, along with two development milestones, USD 3.5 million in total. Lytix stands to receive up to USD 110 million in aggregate payments upon achieving specified clinical, regulatory, and sales milestones, in addition to tiered royalties on worldwide annual net sales, ranging from the low double digits to mid-teens.

Verrica intends to focus initially on basal cell and squamous cell carcinoma as the lead indications for development for Ruxotemitide. Basal cell carcinoma, the most prevalent form of cancer globally, continues to see rising incidence rates, with approximately 3-4 million new cases diagnosed annually in the U.S. alone. BCC predominantly affects sun-exposed areas of the body, with around 80% of cases occurring on the face and head. Given the high unmet need for new treatment options, Ruxotemitide presents a compelling alternative to traditional invasive surgery, offering significant advantages such as reduced pain, infection, bleeding, and scarring. With a projected global market size of USD 11.5 billion by 2028 (CAGR 7.9%), Ruxotemitide is well-positioned to meet the growing demand for more effective BCC therapies.

In August 2024, Verrica announced positive top-line results from its ongoing Phase II trial, demonstrating compelling efficacy of Ruxotemitide in basal cell carcinoma. The data showed high rates of complete clearance and meaningful tumor size reduction, underscoring Ruxotemitide’s potential as a non-surgical alternative for patients with skin cancers. These results not only validate the therapeutic promise of Ruxotemitide in dermatological oncology but also provide a strong foundation for advancing the program toward late-stage development. The outcome reinforces the commercial potential of the Verrica partnership and represents a significant step toward bringing an innovative, less invasive treatment option to a large and underserved patient population.

Risks and Uncertainties

FINANCIAL RISKS

Lytix is a clinical-stage biotech company currently incurring financial losses, which are expected to continue through the development phases of its products. Aside from potential milestone payments from the licensing agreement with Verrica, the company does not anticipate revenue-generating operations until one or more products are commercialized.

The company has no interest-bearing debt, and while bank deposits are exposed to interest rate fluctuations, the impact on financial income is minimal. Lytix regularly conducts transactions in currencies other than NOK, exposing it to currency risk, particularly in relation to EUR- and USD-denominated transactions. Credit risk remains low due to minimal revenue, excluding public grants and drug supply sales to partners.

Lytix manages its cash flow through rolling cash forecasts, with no loan covenants or other financial restrictions in place. The company relies on external funding, primarily through equity contributions, to finance ongoing operations. There is an inherent risk in securing future financing, which depends on the company's performance and broader financial market conditions. Access to capital or financing may be constrained or available only on unfavorable terms.

NON-FINANCIAL RISKS

Lytix focuses on the development of pharmaceutical medications, a capital-intensive process fraught with significant risk until regulatory approval is achieved. The company's cancer treatment candidates and technology platform face risks at every stage of development.

TECHNOLOGY RISK

The company's product candidates are in early development stages, and preclinical or clinical studies may not yield successful outcomes. Continued research and development are essential but may face delays or higher-than-expected costs.

COMPETITIVE TECHNOLOGY

The immunotherapy and cancer therapeutics sectors are highly competitive and rapidly evolving. Lytix operates in this dynamic environment, where competing treatments may affect the company's ability to complete clinical trials, secure marketing authorization, or achieve future sales if approval is granted.

MARKET RISKS

The company's financial success hinges on securing favorable partner agreements and achieving market access with attractive pricing and reimbursement. There are no guarantees that these conditions will be met. Additionally, the company requires approvals from the European Medicines Agency (EMA) for the European market, the U.S. Food and Drug Administration (FDA) for the U.S. market, and equivalent regulatory authorities in other jurisdictions to commercialize its products globally.

Outlook

Lytix Biopharma enters the second half of 2025 with a clear roadmap and several significant milestones ahead. For our partner Verrica, alignment with the FDA paves the way for initiation of a pivotal Phase III program for Ruxotemitide in basal cell carcinoma, with additional genomic and immune response data from the Phase II study expected later this year, alongside a comprehensive overview of the basal cell carcinoma program.

For Lytix, the most decisive near-term event will be the interim results from the NeoLIPA trial in early-stage melanoma, expected in the second half of 2025. These data will not only provide the first clinical readout of Ruxotemitide in the neoadjuvant setting but will also be central in determining the optimal development path forward. Depending on the strength of the results, the outcome could support direct engagement with regulators on an accelerated approval pathway or define the scope of a Phase II study leading into a registrational Phase II/III trial.

In parallel, we continue to progress LTX-401 within our broader pipeline. LTX-401 represents an important long-term opportunity, and we are evaluating the most effective path to bringing this promising candidate into clinical development.

These developments, together with a strong financial position and an expanding network of strategic collaborations, position Lytix to maintain momentum. The coming months will be defined by critical clinical results and partnership milestones that have the potential to shape the future trajectory of our pipeline and create lasting value for both patients and shareholders.

Oslo, August 28, 2025
The Board of Directors and the Chief Executive Officer of Lytix Biopharma AS

Eric Falcand
Chairperson of the Board

Brynjar Forbergskog
Board Member

Claus Andersson
Board Member

Julie Dehaene-Puype
Board Member

Kjetil Hestdal
Board Member

Marie-Louise Fjällskog
Board Member

Øystein Rekdal
Chief Executive Officer

Financial statements

STATEMENT OF COMPREHENSIVE INCOME

Amounts in NOK thousands	*Notes*	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	FY 2024
Revenue	*5,6*	-	-	-	10,526	11,134
Other operating income		-	-	-	-	-
Total operating income		**-**	**-**	**-**	**10,526**	**11,134**
Payroll and related expenses	*7, 8*	(3,546)	(4,715)	(7,651)	(10,378)	(22,590)
Depreciation and amortization expenses		(249)	(230)	(508)	(472)	(915)
Direct R&D expenses	*7*	3,209	(13,170)	(3,068)	(33,356)	(72,565)
Other expenses	*7*	(4,571)	(3,424)	(7,381)	(6,545)	(10,960)
Total operating expenses		**(5,157)**	**(21,540)**	**(18,608)**	**(50,751)**	**(107,029)**
Loss from operations		**(5,157)**	**(21,540)**	**(18,608)**	**(40,225)**	**(95,896)**
Financial income	*9*	165	229	742	739	2,184
Financial expenses	*9*	(58)	(124)	(119)	(131)	(553)
Net financial items		**107**	**105**	**623**	**608**	**1,631**
Loss before tax		**(5,051)**	**(21,435)**	**(17,984)**	**(39,617)**	**(94,265)**
Tax expense		-	-	-	-	-
Loss for the period		**(5,051)**	**(21,435)**	**(17,984)**	**(39,617)**	**(94,265)**
Net other comprehensive income (loss), net of tax						
Items that may be reclassified to profit and loss in subsequent periods		-	-	-	-	-
Items that will not be reclassified to profit and loss in subsequent periods		-	-	-	-	-
Total comprehensive loss for the period		**(5,051)**	**(21,435)**	**(17,984)**	**(39,617)**	**(94,265)**
Earnings (loss) per share						
Basic and diluted earnings (loss) per share	*12*	(0.07)	(0.48)	(0.26)	(0.88)	(1.74)

STATEMENT OF FINANCIAL POSITION

Amounts in NOK thousands	*Notes*	30.06.2025	30.06.2024	31.12.2024
Assets				
Non-current assets				
Property, plant and equipment		18	76	42
Right-of-use assets	*10*	2,565	2,998	2,589
Total non-current assets		**2,583**	**3,074**	**2,631**
Current assets				
Other receivables		7,281	14,410	13,113
Short-term financial investments		60,072	-	-
Cash and cash equivalents		40,191	60,181	130,791
Total current assets		**107,544**	**74,591**	**143,904**
Total assets		**110,127**	**77,665**	**146,535**
Shareholder's equity and liabilities				
Issued capital and reserves				
Share capital	*11*	6,826	4,961	6,816
Share premium reserve		83,198	54,260	101,078
Total equity		**90,024**	**59,221**	**107,894**
Liabilities				
Non-current liabilities				
Lease liabilities	*10*	1,720	2,266	1,878
Total non-current liabilities		**1,720**	**2,266**	**1,878**
Current liabilities				
Trade payables		2,715	4,196	5,015
Other current liabilities		14,730	11,251	30,987
Lease liabilities	*10*	938	731	762
Total current liabilities		**18,383**	**16,178**	**36,764**
Total liabilities		**20,103**	**18,444**	**38,641**
Total equity and liabilities		**110,127**	**77,665**	**146,535**

Oslo, August 28, 2025
The Board of Directors and the Chief Executive Officer of Lytix Biopharma AS

Eric Falcand
Chairperson of the Board

Brynjar Forbergskog
Board Member

Claus Andersson
Board Member

Julie Dehaene-Puype
Board Member

Kjetil Hestdal
Board Member

Marie-Louise Fjällskog
Board Member

Øystein Rekdal
Chief Executive Officer

STATEMENT OF CASH FLOWS

Amounts in NOK thousands	*Notes*	Q2 2025	Q2 2024	H1 2025	H1 2024	FY 2024
Cash flows from operating activities						
Profit (loss) before income tax		(5,051)	(21,435)	(17,984)	(39,617)	(94,265)
Adjustments for:						
Depreciation of property, plant and equipment		8	17	24	34	68
Depreciation of right-of-use assets	*10*	242	213	483	438	847
Interest income/(expense), net		(108)	(182)	(308)	(363)	(1,503)
Share-based payment expense	*8*	(86)	(105)	115	529	878
Increased/decreased in trade and other receivables		2,075	4,430	5,832	(1,633)	(336)
Increased/decreased in trade and other payables		(14,604)	4,147	(18,557)	3,383	23,938
Cash generated from operations		**(17,526)**	**(12,914)**	**(30,395)**	**(37,229)**	**(70,372)**
Income tax paid		-	-	-	-	-
Net cash flows from operations		**(17,526)**	**(12,914)**	**(30,395)**	**(37,229)**	**(70,372)**
Investing activities						
Investment in tangible assets		-	-	-	-	-
Interests received		112	182	314	363	1,510
Investment in other short-term investments		(60,072)	13,511	(60,072)	23,183	23,183
Net cash from/(used in) financing activities		**(59,960)**	**13,693**	**(59,759)**	**23,547**	**24,693**
Financing activities						
Interests paid		(3)	-	(6)	-	(7)
Proceeds from share issue	*11*	-	50,000	-	50,000	161,295
Transaction cost	*11*	-	(3,011)	-	(3,011)	(11,333)
Payment of principal portion of lease liabilities	*10*	(223)	(249)	(441)	(491)	(849)
Net cash from/(used in) financing activities		**(226)**	**46,740**	**(447)**	**46,498**	**149,105**
Net increase in cash and cash equivalents		(77,712)	47,519	(90,600)	32,816	103,426
Cash and cash equivalents at the beginning of the period		117,903	12,661	130,791	27,365	27,365
Cash and cash equivalents at the end of the period		**40,191**	**60,181**	**40,191**	**60,181**	**130,791**

STATEMENT OF CHANGES IN EQUITY

Amounts in NOK thousands	Share capital	Share premium reserve	Other equity	Total equity
Balance as at January 1, 2024	**4,007**	**47,312**	**-**	**51,319**
Loss for the period	-	-	(39,617)	(39,617)
Net other comprehensive income/(loss)	-	-	-	-
Other comprehensive income/(loss) for the period	-	**-**	**(39,617)**	**(39,617)**
Capital increase 13.05.2024	954	49,046	-	50,000
Transaction cost	-	(3,011)	-	(3,011)
Share based payment	-	529	-	529
Reclassification of accumulated losses	-	(39,617)	39,617	-
Total contribution by and distributions to owners	**954**	**(6,947)**	**39,617**	**47,519**
Balance as at June 30, 2024	**4,961**	**54,260**	**-**	**59,221**
Balance as at January 1, 2025	**6,816**	**101,078**	**-**	**107,894**
Loss for the period	-	-	(17,984)	(17,984)
Net other comprehensive income/(loss)	-	-	-	-
Other comprehensive income/(loss) for the period	**-**	**-**	**(17,984)**	**(17,984)**
Share based payment	-	115	-	115
Reclassification of accumulated losses	-	(17,984)	17,984)	-
Share issue	10	(10)	-	-
Total contribution by and distributions to owners	**10**	**(17,880)**	**17,984**	**115**
Balance as at June 30, 2025	**6,826**	**83,198**	**-**	**90,024**

Notes to the interim report

1. GENERAL INFORMATION

The accompanying interim financial statements of Lytix Biopharma AS, for the period ending June 30th, 2025 and the comparable financial statements for the period ending June 30th, 2024, were authorized for issue on August 28th, 2025, by resolution of the Board of Directors.

Lytix Biopharma AS (the 'Company' or 'Lytix Biopharma') is a limited liability company incorporated and domiciled in Norway. The Company was established in 2003, and the registered office is located at Sandakerveien 138, 0484 Oslo. The Company's shares are currently traded on Euronext Growth Oslo.

Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy. The company's lead product, Ruxotemitide (LTX-315), is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. [It is currently being tested in combination with the market approved immunotherapeutic drug KEYTRUDA® (pembrolizumab) in a Phase II study in the US and Europe. The Company is also supporting its licensing partner Verrica Pharmaceuticals in their Phase II trial in patients with basal cell carcinoma. In addition, the company has other candidates in the pipeline, including LTX-401, a second-generation molecule developed for the treatment of visceral tumors.

As of 30 June 2025, Lytix Biopharma AS has no subsidiaries or affiliated companies.

The financial statements for the year ended 31 December 2024 are available at www.lytixbiopharma.com

2. BASIS FOR PREPARATION

These interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 "Interim Financial Reporting" as adopted by the European Union (the "EU") and additional requirements in the Norwegian Securities Trading Act. This interim financial report does not include all information and disclosures required by other standards IFRS® Accounting Standards as adopted by the EU ("IFRS") for a complete set of annual financial statements. Hence, this report should be read in conjunction with the annual report prepared in accordance with IFRS for the year ended 31 December 2024.

These interim financial statements are unaudited.

The accounting policies applied by the Company in these interim financial statements are the same as those applied by the Company in its financial statements for the year ended 31 December 2024.

In the interim financial statements, the first half-year is defined as the reporting period from 1 January to 30 June and the second quarter the period starting from 1 April to 30 June.

All amounts are presented in NOK thousand (TNOK) unless otherwise stated. Because of rounding differences, numbers or percentages may not add up to the sum totals.

Significant accounting judgements, estimates and assumptions

Management makes estimates and assumptions that affect the reported amounts of assets and liabilities within the next financial year. Estimates and judgments are evaluated on an on-going basis and are based on historical experience and other factors, including expectations of future events that are considered to be relevant.

In preparing these condensed interim financial statements, the significant judgements made by management in applying the group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the financial statements for the year ended 31 December 2024.

3. SIGNIFICANT CHANGES, EVENTS AND TRANSACTIONS IN THE CURRENT REPORTING PERIOD

The financial position and the performance of the company was not particularly affected by any significant events or transactions during the first half-year in 2025.

4. PROFIT AND LOSS INFORMATION

Seasonality of operations

Seasonality in pharmaceutical operations is first and foremost associated with outbreaks of certain diseases during certain periods of the year. Such fluctuations are not commonly observed in the incidence rates of cancer. Therefore, management does not consider the business to be 'highly seasonal' in accordance with IAS 34.

NOTE 5 REVENUE

The following table presents the disaggregation of the Company's revenue from contracts with customers:

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Revenue					
Licensing of Ruxotemitide	-	-	-	-	-
Sale of API Ruxotemitide	-	-	-	10,526	10,526
Other revenue	-	-	-	-	607
Total Revenue	**-**	**-**	**-**	**10,526**	**11,134**

In the first half of 2025, Lytix did not record revenue from the licensing agreement or from sales of the active pharmaceutical ingredient (API). This compares to revenues of USD 10.5 million in the first half of 2024, when API sales of Ruxotemitide to our licensee, Verrica Pharmaceuticals, contributed positively to reported income.

NOTE 6 SEGMENTS

Lytix' primary business is to develop proprietary intellectual property of drug candidates for out-licensing, and the production and sale of API (Ruxotemitide) to its licensees. Operating segments are components of the Company that the chief operating decision maker of the Company ('CODM') regularly reviews to assess performance and allocate resources. The CODM for the Company is considered to be the Board of Directors collectively, which reviews the Company's performance as a whole, and therefore only one operating segment is identified.

The geographical distribution of sales by the client's place of incorporation is the following:

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Geographical distribution					
Norway	-	-	-	-	-
US	-	-	-	10,526	11,134
Total operating income	**-**	**-**	**-**	**10,526**	**11,134**

All non-current assets (other than financial instruments) are located in Norway.

Note 5 includes a disaggregation of revenue by the main products and services provided by the Company.

NOTE 7 GOVERNMENT GRANTS

Government grants are recognized in profit or loss as deduction on Salary, Direct R&D expenses and Other operating expenses with the following amounts:

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Government grants					
Tax refund (across all R&D activities)	-	1,187	1,187	2,375	4,750
Oslo Regional Research Fund (RRF)	-	-	-	-	-
Total government grants received	**-**	**1,187**	**1,187**	**2,375**	**4,750**

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Costs deducted					
Payroll and related expenses	-	35	20	95	139
Direct R&D expenses	-	1,153	1,167	2,273	4,604
Other operating expenses	-	-	-	7	7
Total costs deducted	**-**	**1,187**	**1,187**	**2,375**	**4,750**

NOTE 8 PAYROLL AND RELATED EXPENSES

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Payroll and related expenses, including directors, comprise					
Salaries and bonus	2,475	3,655	5,790	7,734	18,011
Defined contribution pension cost	233	241	347	577	1,043
Share-based payment expense	(86)	(105)	115	529	878
Social security contributions	877	935	1,328	1,582	2,704
Other personnel costs	47	24	92	50	92
Government grants	-	(35)	(20)	(95)	(139)
Total payroll and related expenses	**3,546**	**4,715**	**7,651**	**10,378**	**22,590**

NOTE 9 FINANCE INCOME AND EXPENSES

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Financial income					
Interest income	112	181	314	363	1,510
Foreign exchange gains	(29)	-	347	-	298
Other financial income	81	48	81	376	376
Total financial income	**165**	**229**	**742**	**739**	**2,184**

Amounts in NOK thousands	**Q2 2025**	Q2 2024	**H1 2025**	H1 2024	**2024**
Financial expenses					
Interest expenses	(3)	-	(6)	-	(7)
Interest expenses on lease liabilities	(53)	(3)	(111)	(9)	(119)
Foreign exchange losses	-	(74)	-	(74)	(379)
Other financial expenses	(1)	(47)	(2)	(48)	(48)
Total financial expenses	**(58)**	**(124)**	**(119)**	**(131)**	**(553)**

NOTE 10 LEASES

The lease for the current office space was extended in June 2024 following its scheduled expiry. In accordance with IFRS 16, Lytix recalculated the right-of-use asset and corresponding lease liability during the first half of 2025 to reflect the updated lease terms.

NOTE 11 SHARE CAPITAL AND SHAREHOLDER INFORMATION

Share capital on June 30, 2025, is NOK 6,826,200.2 (December 31, 2024: 6,815,943.4), being 68,262,002 ordinary shares at a nominal value of NOK 0.1. All shares carry equal voting rights.

	2025	**2024**
Ordinary shares at 1 January	68,159,434	40,068,319
Capital increase May 13th, 2024 [1)]	n/a	9,541,984
Capital increase December 23rd, 2024 [2)]	n/a	18,549,131
Share issue January 15, 2025 [3)]	102,568	n/a
Ordinary shares per June 30 / December 31	**68,262,002**	**68,159,434**

[1)] In May 2024, 9,541,984 shares were subscribed for in a private placement among existing shareholders at an average share price of NOK 5.24 for total gross proceeds of NOK 50 million. On April 25th, 2024, the extraordinary general meeting resolved to issue 9,055,607 shares and further authorized the board of directors to issue additional shares. On April 26th, the board of directors resolved to issue 486,377 shares. The final allocation thus amounts to 9,541,984 shares, raising gross proceeds of NOK 50 million. The contribution was confirmed and registered in the Norwegian Register of Business Enterprises on May 13, 2024.

[2)] In December 2024, 18,549,131 shares were subscribed for in a private placement among existing shareholders and new investors at a share price of NOK 6.00 for total gross proceeds of NOK 111.3 million. On December 17th, 2024, the Board resolved to issue 18,549,131 shares. The contribution was confirmed and registered in the Norwegian Register of Business Enterprises on December 23rd, 2024.

[3)] In January 2025, 102,568 shares were issued to partly settle the underwriting fee related to the Private Placement completed in December 2024. The shares were issued at a subscription price of NOK 0.10, corresponding to total gross proceeds of NOK 10,256.8. The Board of Directors resolved the share issue on December 17, 2024, and the capital increase was confirmed and registered with the Norwegian Register of Business Enterprises on January 15, 2025.

No.	Shareholder	No. of shares	Percentage share of total no. of shares
1	JAKOB HATTELAND HOLDING AS	6,895,190	10.1 %
2	Citibank, N.A.	4,896,422	7.1 %
3	TAJ HOLDING AS	4,496,593	6.5 %
4	SATURN INVEST AS	4,485,579	6.5 %
5	Skandinaviska Enskilda Banken AB	2,500,000	3.6 %
6	LYR INVEST AS	2,438,863	3.5 %
7	BRØDRENE KARLSEN HOLDING AS	2,283,507	3.3 %
8	PER STRAND EIENDOM AS	2,019,102	2.9 %
9	3T PRODUKTER HOLDING AS	1,808,764	2.6 %
10	LYSNES INVEST AS	1,448,987	2.1 %
11	YNNI INVEST AS	1,392,889	2.0 %
12	HIFO INVEST AS	1,318,913	1.9 %
13	KVASSHØGDI AS	1,307,652	1.9 %
14	NORDNET LIVSFORSIKRING AS	1,284,767	1.8 %
15	CARE HOLDING AS	1,006,512	1.4 %
16	BELVEDERE AS	955,027	1.3 %
17	LTH INVEST AS	896,786	1.3 %
18	DRAGESUND INVEST AS	685,436	1.0 %
19	JPB AS	590,839	0.8 %
20	NORINNOVA INVEST AS	557,510	0.8 %
	Total number of shares for top 20 shareholders	**43,269,338**	**63.4%**
	Total number of shares for the other shareholders	**24,992,664**	**36.6%**
	Total number of shares	**68,262,002**	**100.0%**

NOTE 12 EARNINGS PER SHARE

Earnings per share are calculated on the basis of the profit or loss for the year after tax, excluding other comprehensive items. The result is divided by a time weighted average number of outstanding shares over the year. The diluted earnings per share is calculated by adjusting the time weighted average number of outstanding shares by the number of employee share options that can be exercised. As the company is currently loss-making an increase in the average number of shares would have anti-dilutive effect.

	Q2 2025	Q2 2024	**H1 2025**	H1 2024	**2024**
Loss for the period *(NOK thousands)*	(5,051)	(21,435)	(17,984)	(39,617)	(94,265)
Average number of outstanding shares during the year	68,262,002	44,839,311	68,210,718	44,839,311	54,113,872
Basic and diluted earnings per share *(NOK)*	**(0.07)**	**(0.48)**	**(0.26)**	**(0.88)**	**(1.74)**

NOTE 13 EVENTS AFTER THE REPORT DATE

The Board of Directors is not aware of any other events that occurred after the balance sheet date, or any new information regarding existing matters, that can have a material effect on the 2025 first half-year interim financial report for the company.

Lytix Biopharma AS
Sandakerveien 138
NO-0484 Oslo
Norway

General enquiries:
post@lytixbiopharma.com

Media enquiries:
oystein.rekdal@lytixbiopharma.com

www.lytixbiopharma.com